# Development of explicit definitions of potentially inappropriate prescriptions for antidiabetic drugs in people with type 2 diabetes: A Delphi survey and consensus meeting

**Authors:** Erwin Gerard, Derya Bugday, Matthieu Calafiore, Jan Baran, Sophie Gautier, Heloïse Henry, Bertrand Decaudin, Madleen Lemaitre, Nicolas Baclet, Paul Quindroit, Anne Vambergue, Jean-Baptiste Beuscart, Sairah Hafeez Kamran, Sairah Hafeez Kamran, Sairah Hafeez Kamran

PMC · DOI: 10.1371/journal.pone.0334836 · PLOS One · 2025-10-22

## TL;DR

This study created a list of inappropriate antidiabetic drug prescriptions for type 2 diabetes patients through expert consensus.

## Contribution

A validated list of 41 explicit definitions of inappropriate antidiabetic prescriptions for type 2 diabetes was developed.

## Key findings

- 41 explicit definitions of PIPs were validated across four categories.
- Experts from multiple countries and professions participated in the Delphi survey.
- The list can be used in clinical decision support systems to detect inappropriate prescriptions.

## Abstract

Explicit definitions for potentially inappropriate prescriptions (PIPs) are useful for optimizing drug use. The objective of the present study was to validate a list of definitions of PIPs for antidiabetic drugs in a Delphi survey with general practitioners, diabetologists, community pharmacists, hospital pharmacists and pharmacologists from mainland France, Belgium, and Switzerland.

The experts gave their opinion on each explicit definition and could suggest new definitions. Definitions with a 1-to-9 Likert score of between 7 and 9 from at least 75% of the participants were validated. The results were discussed during consensus meetings after each round.

46 participants were recruited, and 38 (82.6%) completed the survey. The Delphi survey resulted in a consensus list of 41 explicit definitions of PIPs for antidiabetic drugs in four groups: (i) the need to temporarily discontinue a medication in the event of acute illness (n = 9; 22%), (ii) the need to review and adjust the dosing regimen (n = 26; 36.6%), (iii) the initiation of an inappropriate drug (n = 3; 7.3%), and (iv) the need for further monitoring of a people with type 2 diabetes (n = 3; 7.3%).

The list is specific for antidiabetic drugs (other than insulin) for people with type 2 diabetes. This explicit list could be implemented in a clinical decision support system for the automatic detection of PIPs and might help healthcare professionals involved in the management of people living with type 2 diabetes.

## Linked entities

- **Diseases:** type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** type 2 diabetes (MESH:D003924)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12543176/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12543176/full.md

## References

80 references — full list in the complete paper: https://tomesphere.com/paper/PMC12543176/full.md

---
Source: https://tomesphere.com/paper/PMC12543176